MONTREAL, Jan. 14, 2025 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that eligible patients in Ontario now have access to Pluvicto™ (lutetium (177 Lu ...
Next up, prostate cancer drug Pluvicto, a newcomer to the list in November, jumped two spots to take sixth, as Novartis bumped up TV ad spending for the radiotherapy from $21.3 million in November ...
MONTREAL, Jan. 14, 2025 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that eligible patients in Ontario now have access to Pluvicto™ (lutetium (177Lu ...
MONTREAL, Jan. 14, 2025 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that eligible patients in Ontario now have access to Pluvicto™ (lutetium (177 Lu) vipivotide ...
Health Canada approved Pluvicto in August 2022, but patients have been waiting since then for provincial health plans to announce coverage. Health Minister Sylvia Jones says Ontario is the first ...
LONDON — The Ontario government is connecting more people to care by being the first Canadian jurisdiction to publicly fund and administer PLUVICTO TM a new treatment for advanced-stage prostate ...
Hosted on MSN15d
Ontario funding new treatment for advanced-stage prostate cancerTORONTO — Ontario's health minister says the province will now publicly fund a new treatment for advanced-stage prostate cancer. Health Canada approved Pluvicto in August 2022, but patients have ...
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback